{
  "id": 7491490,
  "title": "GSK acquires T cell-engager for multiple myeloma treatment",
  "url": "https://urgent.news/2026/09/15/gsk-acquires-t-cell-engager-for-multiple-myeloma-treatment",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T06:41:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/gsk-acquires-t-cellengager-for-multiple-myeloma-treatment-93CH-4900858"
  },
  "original_language": "en",
  "account": "London - Pharmaceutical giant GSK has acquired a trispecific T cell-engager from privately held biotech firm Chimagen Biosciences, aimed at treating multiple myeloma, according to a press release. The innovative drug can bind to T cells while simultaneously targeting two tumor-associated antigens. Once in phase I trials in 2027, GSK will pay an upfront fee to secure global rights to the treatment. Chimagen will receive development and commercial milestone payments. The $750 million agreement, subject to customary conditions, bolsters GSK's oncology portfolio and advances its blood cancer leadership goals, said Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D at GSK.",
  "summary": null,
  "key_points": [
    "GSK acquires trispecific T cell-engager from Chimagen Biosciences",
    "Drug targets two tumor-associated antigens in multiple myeloma treatment",
    "$750 million deal strengthens GSK's oncology portfolio"
  ],
  "editors_take": "GSK's acquisition of the trispecific T cell-engager strengthens its oncology portfolio and advances its blood cancer leadership goals with a new treatment approach targeting multiple myeloma.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}